3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
11
Neoplasms
3
Lung Neoplasms
2
Carcinoma, Hepatocellular
2
Stomach Neoplasms
1
Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available
1
Non-Small Cell Lung Cancer Metastatic
1
Hematologic Neoplasms
1
Gastrointestinal Neoplasms
1
Deafness, Autosomal Recessive 39
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Adenocarcinoma
1
Interventions
Oxaliplatin
29
Fluorouracil
25
Leucovorin
20
Capecitabine
18
Irinotecan
17
Bevacizumab
14
Cisplatin
12
Surveys and Questionnaires
11
Gemcitabine
9
Drug Therapy
9
Standard of Care
8
Nivolumab
7
Cetuximab
7
pembrolizumab
6
S 1 (combination)
6
Cyclophosphamide
6
atezolizumab
5
Specimen Handling
5
Endoscopic Mucosal Resection
5
Educational Status
5
Docetaxel
5
Blood Specimen Collection
5
fludarabine
4
aldesleukin
4
Radiotherapy
4
Radiosurgery
4
Pemetrexed
4
IFL protocol
4
Folfox protocol
4
Everolimus
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Gastrointestinal Neoplasms
×
tepotinib
×
Clear all
NCT04591431
2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2
Unknown
400 enrolled